Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes
- 10 February 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 109 (5), 641-646
- https://doi.org/10.1161/01.cir.0000112570.97220.89
Abstract
Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndrome patients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials. We describe the problems with these analytical techniques and demonstrate that different approaches to the question can result in opposing answers. Clinical-practice decisions and practice guidelines should be based on overall trial results and not analyses of post-randomization subgroups.This publication has 23 references indexed in Scilit:
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 2001
- Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive managementThe American Journal of Cardiology, 2001
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Subgroup analysis and other (mis)uses of baseline data in clinical trialsThe Lancet, 2000
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyThe Lancet, 1997
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-IIThe Lancet, 1997
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyThe New England Journal of Medicine, 1994
- Analysis of clinical trial outcomes: Some comments on subgroup analysesControlled Clinical Trials, 1989
- SUBGROUP ANALYSISThe Lancet, 1988